TRCT
CPXX

Tower Research Capital (TRC)’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,896
Closed -$57K – 5210
2016
Q2 		$57K Buy
1,896
+1,697
+853% +$34.4K 0.01% 1472
2016
Q1 		$2K Sell
199
-802
-80% -$2.63K ﹤0.01% 3574
2015
Q4 		$2K Buy
1,001
+976
+3,904% +$1.67K ﹤0.01% 3943
2015
Q3 		$0 Sell
25
-1,164
-98% -$2.58K ﹤0.01% 5388
2015
Q2 		$3K Buy
1,189
+249
+26% +$565 ﹤0.01% 3645
2015
Q1 		$2K Sell
940
-2,445
-72% -$6.58K ﹤0.01% 3929
2014
Q4 		$7K Buy
+3,385
New +$7.02K ﹤0.01% 2529
2014
Q1 		– Sell
-540
Closed -$2K – 5318
2013
Q4 		$2K Buy
+540
New +$1.85K ﹤0.01% 4113

Tower Research Capital (TRC)'s CPXX Position: Q3 2016 in Review

Tower Research Capital (TRC) sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q3 2016, closing a stake of 1,896 shares — an estimated $57K sold.

Tower Research Capital (TRC) first reported a position in CPXX in Q4 2013 and held it in 8 quarters. The position peaked at $57K in Q2 2016. 0 funds tracked by Wall St. Rank hold CPXX as of Q3 2016.

  • Tower Research Capital (TRC) reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q3 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,896 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q3 2016, an estimated $57K.
  • Tower Research Capital (TRC) first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q4 2013 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $57K in Q2 2016.
  • 0 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q3 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2016, filed 8 Nov 2016.